Cell Therapy News/Articles, page-5721

@RickyH I would suggest that if it was used along with best standard of care there would be little to lose as it's safety profile has been well documented. In regards to evidence, whilst there is no P3 data yet there have been a number of smaller trials (not all MSB of course) and EAP's which have produced promising data. Remembering this is an SAS and not access to approved treatments. PAR's iPPS for instance is available via the SAS here in Australia. The real issues would be finding doctors who are aware of the treatment and then actually being able to source remestemcel-l. My own hope was that something along the lines of an EAP (do we run those in Australia?) could be set up however I understand that the Mesoblast team are stretched at the moment and this would also require collaboration with the relevant bodies here.